SH
SHC
SHC What Sotera Health promised, and what happened
Guidance
What management said, and what became of it
14 of 15 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Long-term net leverage target range | 2.0x to 4.0x | Sep 2024 | Our net leverage ratio further improved to 3x for the second quarter, marking an important milestone as we reached our long-term target leverage range of 2 to 3x | Achieved |
| Nordion first-half revenue share of full-year | approximately 40% to 45% of full-year 2026 revenue | Dec 2025 | As discussed on our last earnings call, we expected Nordion's first half 2026 revenue to represent approximately 40% to 45% of Nordion's full year revenue. First half revenue finished above that range, driven by certain shipments anticipated in the second half that occurred in the second quarter. | Missed |
| Full-year adjusted EBITDA growth | 5.5% to 7% constant currency | Dec 2025 | We expect adjusted EBITDA to grow to a range of $634 million to $643 million, representing 5.75% to 7.25% constant currency growth and an estimated 100 basis point foreign currency benefit. | Revised Up |
The full ledger
Open Sotera Health’s full ledger
A free account opens 5 company ledgers a month. All 40 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 40 tracked commitments for Sotera Health
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.